Angiographic and clinical outcome following sirolimus-eluting stent (Cypher) implantation. A single center experience.
OBJECTIVE
To investigate the late outcomes of sirolimus-eluting stent implantation in patients with coronary artery disease.


BACKGROUND
Drug-eluting stents reduce intimal hyperplasia, which is the main cause of in-stent restenosis. Sirolimus-eluting stents significantly reduce clinical and angiographic restenosis and improve event-free survival.


METHODS
The study population consisted of 207 patients (273 stents) who had undergone coronary Cypher stent implantation. Patients were eligible for enrollment if there was symptomatic coronary artery disease or positive exercise testing, and angiographic evidence of single or multivessel disease with a target lesion stenosis of > or = 70% in a > or = 2.25 mm vessel. Follow-up coronary angiography was performed 18 months after stent deployment. Patients were followed-up for a mean of 24.7 +/- 7.4 months.


RESULTS
All patients survived after stent implantation, but 5 (2.4%) patients experienced acute ST elevation myocardial infarction and 4 (1.9%) patients developed non-Q wave myocardial infarction following angioplasty. Recurrent angina pectoris was observed in 16 (7.7%) patients (11 stable angina pectoris and 5 unstable angina pectoris). Angiographic evidence of restenosis was observed in these 20 (9.66%) patients. The 5 other patients had noncritical angiographic restenosis. Eleven (5.3%) patients underwent angioplasty because of restenosis, and coronary artery bypass grafting was conducted in the other 9 (4.3%) patients.


CONCLUSIONS
The results of the present study indicate that Cypher stents could be implanted with a very high success rate and have encouraging long-term angiographic and clinical results.
Ozcan
Turkay
T
Department of Cardiology, Faculty of Medicine, Mersin University, Mersin, Turkey.
Cin
V Gokhan
VG
Yurtdas
Mustafa
M
Akcay
Burak
B
Seyis
Sabri
S
Acele
Armagan
A
Cicek
Dilek
D
Camsari
Ahmet
A
Akkus
Necdet
N
Doven
Oben
O
D000787:Angina Pectoris / Q000000981:diagnostic imaging / Q000601:surgery*; D019917:Blood Vessel Prosthesis Implantation / Q000295:instrumentation*; D020099:Coated Materials, Biocompatible; D017023:Coronary Angiography; D023903:Coronary Restenosis / Q000000981:diagnostic imaging / Q000401:mortality / Q000517:prevention & control*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009204:Myocardial Revascularization / Q000379:methods; D011379:Prognosis; D020123:Sirolimus / Q000627:therapeutic use*; D015607:Stents; D015996:Survival Rate; D014421:Turkey / Q000453:epidemiology
D020099:Coated Materials, Biocompatible; D007166:Immunosuppressive Agents; D020123:Sirolimus